Albuterol is a beta2-adrenergic agonist indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. MedsAcross supplies Albuterol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Albuterol Sulfate Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Source: US FDA prescribing information
In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50% of cardiac beta-adrenergic receptors. The precise function of these receptors has not been established. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP).
Source: US FDA prescribing information
For treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms, the usual dosage for adults and children 4 years of age and older is two inhalations repeated every 4 to 6 hours. More frequent administration or a larger number of inhalations is not recommended. In some patients, one inhalation every 4 hours may be sufficient. Each actuation of Albuterol Sulfate Inhalation Aerosol delivers 108 mcg of albuterol sulfate (equivalent to 90 mcg of albuterol base) from the mouthpiece. It is recommended to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks by releasing four “test sprays” into the air, away from the face. Exercise Induced Bronchospasm Prevention: The usual dosage for adults and children 4 years of age and older is two inhalations 15 to 30 minutes before exercise.
Source: US FDA prescribing information
Albuterol Sulfate Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to albuterol or any other Albuterol Sulfate Inhalation Aerosol components.
Source: US FDA prescribing information
Paradoxical Bronchospasm: Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs, Albuterol Sulfate Inhalation Aerosol should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister. Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol Sulfate Inhalation Aerosol than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
Source: US FDA prescribing information
Adverse reaction information concerning Albuterol Sulfate Inhalation Aerosol is derived from a 12-week, double-blind, double-dummy study which compared Albuterol Sulfate Inhalation Aerosol, a CFC 11/12 propelled albuterol inhaler, and an HFA-134a placebo inhaler in 565 asthmatic patients. The following table lists the incidence of all adverse events (whether considered by the investigator drug related or unrelated to drug) from this study which occurred at a rate of 3% or greater in the Albuterol Sulfate Inhalation Aerosol treatment group and more frequently in the Albuterol Sulfate Inhalation Aerosol treatment group than in the placebo group. Overall, the incidence and nature of the adverse reactions reported for Albuterol Sulfate Inhalation Aerosol and a CFC 11/12 propelled albuterol inhaler were comparable.
Source: US FDA prescribing information
Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol Sulfate Inhalation Aerosol, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia which may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Source: US FDA prescribing information
Store between 15° to 25°C (59° to 77°F). For best results, canister should be at room temperature before use. Exposure to temperatures above 120°F may cause bursting. Store the inhaler with the mouthpiece down.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
18 presentations of Albuterol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Albuterol 2.5 mg/3 mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 90 mcg inhalerInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 4 mg tabletOralGeneric name | — | US FDA | Available on request |
| Albuterol 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Albuterol 0.83 mg/mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 0.63 mg/3 mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 1.25 mg/3 mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 90 mcg inhalantInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 2 mg/5 mL syrupOralGeneric name | — | US FDA | Available on request |
| Ventolin HFA 90 mcg inhalerInhalation | GlaxoSmithKline | US FDA | Available on request |
| Albuterol 2.5 mg/0.5 mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
| Albuterol 108 mcg inhalerInhalationGeneric name | — | US FDA | Available on request |
| Albuterol Sulfate HFA 90 mcg inhalerInhalation | Teva Pharmaceuticals | US FDA | Available on request |
| albuterol sulfate HFA 90 mcg inhalerInhalation | A-S Medication Solutions | US FDA | Available on request |
| Albuterol Sulate HFA 90 mcg inhalerInhalation | NuCare Pharmaceuticals,Inc | US FDA | Available on request |
| Albuterol 90 mcg inhalantOralGeneric name | — | US FDA | Available on request |
| ProAir Digihaler 90 mcg inhalantInhalation | Teva Respiratory | US FDA | Available on request |
| ProAir RespiClick 90 mcg inhalation powderInhalation | Teva Respiratory | US FDA | Available on request |
5 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 1 May 1981 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Albuterol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 18 presentations of Albuterol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 6 brand names for Albuterol, including Albuterol Sulate HFA, Albuterol Sulfate HFA, albuterol sulfate HFA, ProAir Digihaler, ProAir RespiClick, Ventolin HFA.
Yes. The US FDA first approved Albuterol on 1 May 1981, according to Drugs@FDA.
No listed presentation of Albuterol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Albuterol is classified under ATC code R03AC02 (Albuterol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.